<DOC>
	<DOCNO>NCT01961856</DOCNO>
	<brief_summary>In PLATO substudy refer patient present ST-elevation Myocardial Infarction ( STEMI ) , 4201 receive ticagrelor , 1326 pre-treated 600mg clopidogrel load dose ( LD ) within 24 hour prior randomization . It logical assumption , patient reload ticagrelor demonstrate reduce platelet reactivity ( PR ) 24 hour , comparison initially load ticagrelor , due synergistic antiplatelet effect . Single load ticagrelor though , possibly accompany small bleed potency compare reload ticagrelor . Therefore , assume single load ticagrelor non-inferior reloading ticagrelor , term platelet reactivity . P2Y12 inhibitor naive patient STEMI , randomize immediately coronary angiography ( Hour 0 ) receive either Ticagrelor 180mg LD Clopidogrel 600mg LD 2 hour later reload Ticagrelor 180mg , write informed consent . PR measure , use VerifyNow assay randomization ( Hour 0 ) 2 , 4 , 6 24 hour post randomization . In addition , 12-lead ECG perform randomization , 90 180 minute first balloon inflation , well exit day . Troponin I CK-MB assess randomization hour 4 , 12 , 24 , 48 72 randomization . Non inferiority Ticagrelor LD versus Ticagrelor re-LD would accept upper bound 2-sided 95 % CI around estimate LS mean difference ( Ticagrelor LD minus Ticagrelor re-LD ) primary end point ( PR 24 hour ) would lie bellow Δ=35 PRU . This non-inferiority margin ( Δ ) represent upper bound LS mean difference PR Ticagrelor Prasugrel arm 24 hour LD pharmacodynamic study 55 STEMI patient . Considering previous study PR 24 hour post randomization estimate 47±40 PRU 41±35 PRU Ticagrelor LD Ticagrelor re-LD group respectively . To obtain 85 % statistical power 2-sided alpha=0.05 , approximately 32 patient treatment group ( 64 total ) would need establish primary hypothesis use abovementioned non-inferiority margin 35 PRU . Anticipating 5 % dropout rate , enrollment set least 68 patient . The primary endpoint , well PR time point study analyze separately via mixed effect model treatment fixed effect , patient random intercept PR baseline covariate . Least square estimate mean difference present , 95 % confidence interval two-sided p-value treatment effect . P value secondary endpoint report two-tailed test superiority .</brief_summary>
	<brief_title>Ticagrelor Loading Dose Versus Clopidogrel Loading Reloading With Ticagrelor .</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Age 1880 year old Patients STEMI ( pain onset &lt; 12 hour ) undergo primary PCI P2Y12 inhibitor naive Written inform consent Periprocedural IΙb/IIIa inhibitor administration Cardiogenic shock/hemodynamic instability Pseudoaneurism , retroperitoneal hematoma , major bleeding ( need transfusion Hb decline≥5 gr/ dl ) Need anticoagulant treatment Current future administration thienopyridines ADP receptor inhibitor Known thrombocytopenia ( &lt; 100.000 / μL ) randomization Hct &lt; 30 % Hct &gt; 52 % randomization Known allergy clopidogrel ticagrelor Recent ( &lt; 6 week ) major operation , include CABG History bleed disorder Known intracranial mass , arteriovenous shunt aneurism Previous intracranial bleeding INR &gt; 1,5 Other clinical condition associate increase bleed risk , accord investigator ' judgment Known creatinine Clearance &lt; 30ml/h randomization hemodialysis Severe/moderate liver failure Pregnancy/ breastfeeding Increased risk bradyarrhythmias , accord investigator 's judgment Administration potent CYP3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , grapefruit juice N1 L/d ) , substrates CYP3A narrow therapeutic range ( cyclosporine , quinidine ) , potent CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) Severe uncontrolled chronic obstructive pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>platelet reactivity</keyword>
	<keyword>ticagrelor load dose</keyword>
	<keyword>clopidogrel load dose</keyword>
</DOC>